How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

Cancer is the second leading cause of mortality in EU countries, and the needs to tackle cancer are obvious. New scientific understanding, techniques and methodologies are opening up horizons for significant improvements in diagnosis and care. However, take-up is uneven, research needs and potential outstrip currently available resources, manifestly beneficial practices—such as population-level screening for lung cancer—are still not generalised, and the quality of life of patients and survivors is only beginning to be given attention it merits. This paper, mainly based on a series of multistakeholder expert workshops organised by the European Alliance for Personalised Medicine (EAPM), looks at some of those specifics in the interest of planning a way forward. Part of this exercise also involves taking account of the specific nature of Europe and its constituent countries, where the complexities of planning a way forward are redoubled by the wide variations in national and regional approaches to cancer, local epidemiology and the wide disparities in health systems. Despite all the differences between cancers and national and regional resources and approaches to cancer care, there is a common objective in pursuing broader and more equal access to the best available care for all European citizens.

[1]  M. Gonen,et al.  PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. , 2022, The New England journal of medicine.

[2]  J. Ptak,et al.  Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. , 2022, The New England journal of medicine.

[3]  A. Roediger,et al.  Should we screen for lung cancer? A 10-country analysis identifying key decision-making factors. , 2022, Health policy.

[4]  A. Lallas,et al.  European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. , 2022, European journal of cancer.

[5]  M. Rugge,et al.  Malignant Melanoma: Direct Costs by Clinical and Pathological Profile , 2022, Dermatology and Therapy.

[6]  N. Rosenfeld,et al.  The future of early cancer detection , 2022, Nature Medicine.

[7]  P. Bousquet,et al.  The French Early Breast Cancer Cohort (FRESH): A Resource for Breast Cancer Research and Evaluations of Oncology Practices Based on the French National Healthcare System Database (SNDS) , 2022, medRxiv.

[8]  A. Nicholson,et al.  Lung Cancer in the United Kingdom. , 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  S. Rudzki,et al.  Title: Risk Factors for the Diagnosis of Colorectal Cancer , 2022, Cancer control : journal of the Moffitt Cancer Center.

[10]  R. Dellamano,et al.  P31 Impact of COVID-19 on HTA/PRMA of Medicinal Products in Europe: A Payer Perspective , 2022, Value in Health.

[11]  J. Machiels,et al.  Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact , 2021, Cancers.

[12]  K. Nackaerts,et al.  Lung Cancer in Belgium. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  A. Gavin,et al.  The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers , 2021, European journal of cancer.

[14]  A. Baird,et al.  The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments , 2021, Cancers.

[15]  M. IJzerman Cost of colorectal cancer care: sufficient to inform cancer policy? , 2021, The lancet. Gastroenterology & hepatology.

[16]  M. Coleman,et al.  The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study. , 2021, The lancet. Gastroenterology & hepatology.

[17]  Pengfei Xu,et al.  Global colorectal cancer burden in 2020 and projections to 2040 , 2021, Translational oncology.

[18]  D. Hellwig Hope for new developments in the reimbursement of oncological PET/CT in Germany. , 2021, Nuklearmedizin. Nuclear medicine.

[19]  L. Wilson,et al.  Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women , 2021, Frontiers in Oncology.

[20]  R. Connolly,et al.  152P Analysis of patient access to breast cancer drugs in the USA and Europe with a focus on the UK and Ireland , 2021, Annals of Oncology.

[21]  G. Veronesi,et al.  Lung cancer screening: who pays? Who receives? The European perspectives , 2021, Translational lung cancer research.

[22]  S. Rudzki,et al.  Risk factors for the diagnosis of colorectal cancer , 2021 .

[23]  R. Mroz,et al.  Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2 , 2021, Contemporary oncology.

[24]  M. Buljan,et al.  A Reminder of Skin Cancer During the COVID-19 Pandemic. , 2021, Acta dermatovenerologica Croatica : ADC.

[25]  K. Pantel,et al.  Liquid Biopsy: From Discovery to Clinical Application. , 2021, Cancer discovery.

[26]  C. Lebbé,et al.  National early access programs and clinical trials: What opportunities for early access to therapeutic innovations for patients with malignant melanoma? , 2021, Cancer.

[27]  B. Guillot,et al.  Access to innovation through the national early access program and clinical trials for patients with malignant melanoma , 2021, Cancer.

[28]  G. Giaccone,et al.  Challenges in Diversity, Equity, and Inclusion in Research and Clinical Oncology , 2021, Frontiers in Oncology.

[29]  M. Garmyn,et al.  Incidence and survival of cutaneous melanoma in Belgium and the Netherlands from 2004 to 2016: striking differences and similarities of two neighbouring countries , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[30]  S. Hua,et al.  Perspectives and controversies regarding the use of natural products for the treatment of lung cancer , 2021, Cancer medicine.

[31]  Adam Barsouk,et al.  Epidemiology of lung cancer , 2021, Contemporary oncology.

[32]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[33]  J. Kononen,et al.  Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study , 2021, The Lancet regional health. Europe.

[34]  M. Sekerija,et al.  Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer , 2021, The European Journal of Health Economics.

[35]  G. Curigliano,et al.  The use of liquid biopsy in early breast cancer: clinical evidence and future perspectives , 2021 .

[36]  P. Giraud,et al.  Lung Cancer in France. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[37]  A. Kent,et al.  Bringing Onco-Innovation to Europe’s Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine , 2020, Cancers.

[38]  M. Sasiadek,et al.  Personalised medicine in lung cancer , 2021 .

[39]  S. Peacock,et al.  Uncertainty tolerance among experts involved in drug reimbursement recommendations: Qualitative evidence from HTA committees in Canada and Poland. , 2020, Health policy.

[40]  O. Solà-Morales,et al.  Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe , 2020, Breast.

[41]  Shimul A. Shah,et al.  Impact of the COVID-19 Pandemic on Lung Cancer Screening Program and Subsequent Lung Cancer , 2020, Journal of the American College of Surgeons.

[42]  P. Hardy,et al.  Clinical Applications of Nanomedicines in Lung Cancer Treatment. , 2020, Acta biomaterialia.

[43]  Health at a Glance: Europe 2020 , 2020, Health at a Glance: Europe.

[44]  F. Bidard,et al.  Clinical utility of circulating tumor cells: an update , 2020, Molecular oncology.

[45]  M. Oudkerk,et al.  Lung cancer LDCT screening and mortality reduction — evidence, pitfalls and future perspectives , 2020, Nature Reviews Clinical Oncology.

[46]  G. Zalcman,et al.  [Epidemiology of lung cancer in France and in the world]. , 2020, La Revue du praticien.

[47]  F. Bazzoli,et al.  Impact of SARS-CoV-2 Pandemic on Colorectal Cancer Screening Delay: Effect on Stage Shift and Increased Mortality , 2020, Clinical Gastroenterology and Hepatology.

[48]  A. Martling,et al.  Improvement of colorectal cancer patient experience with a regional cancer plan in Sweden. , 2020, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[49]  G. Defossez,et al.  Multidimensional penalized splines for incidence and mortality-trend analyses and validation of national cancer-incidence estimates. , 2020, International journal of epidemiology.

[50]  A. Testori,et al.  Adjuvant Therapy for Melanoma: Past, Current, and Future Developments , 2020, Cancers.

[51]  Vibeke G. Dale,et al.  Lung cancer biomarker testing: perspective from Europe , 2020, Translational lung cancer research.

[52]  H. D. de Koning,et al.  Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe , 2020, Cancers.

[53]  G. Ciliberto,et al.  Propelling Health Care into the Twenties , 2020, Biomedicine Hub.

[54]  G. Petrova,et al.  Comparative analysis of the access to health-care services and breast cancer therapy in 10 Eastern European countries , 2020, SAGE open medicine.

[55]  J. Eriksson,et al.  Stated preferences for relapsed or refractory mantle cell lymphoma treatments in Sweden and Germany. , 2020, Future oncology.

[56]  H. Brenner,et al.  Benefits of switching from guaiac-based faecal occult blood to faecal immunochemical testing: experience from the Wallonia–Brussels colorectal cancer screening programme , 2020, British Journal of Cancer.

[57]  M. Jakovljevic,et al.  A Correlation Study of the Colorectal Cancer Statistics and Economic Indicators in Selected Balkan Countries , 2020, Frontiers in Public Health.

[58]  H. Williams,et al.  Algorithm based smartphone apps to assess risk of skin cancer in adults: systematic review of diagnostic accuracy studies , 2020, BMJ.

[59]  H. D. de Koning,et al.  Evidence for reducing cancer-specific mortality due to screening for breast cancer in Europe: A systematic review. , 2020, European journal of cancer.

[60]  A. Lallas,et al.  European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019. , 2020, European journal of cancer.

[61]  Charline Morichon EUROPE'S BEATING CANCER PLAN , 2020 .

[62]  J. Espín,et al.  Evaluation of new medicines in Spain and comparison with other European countries. , 2020, Gaceta sanitaria.

[63]  G. Rossi,et al.  Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. , 2019, Critical reviews in oncology/hematology.

[64]  S. Simoens,et al.  Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price! , 2019, BioDrugs.

[65]  J. Jassem,et al.  Access to Novel Drugs for Non‐Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis , 2019, The oncologist.

[66]  C. Signorelli,et al.  Universal Health Coverage in Italy: lights and shades of the Italian National Health Service which celebrated its 40th anniversary. , 2019, Health policy.

[67]  Meltem Saygılı,et al.  Determining Breast Cancer Treatment Costs Using the Top Down Cost Approach. , 2019, European journal of breast health.

[68]  R. Reintjes,et al.  Analysis of the methodology of skin cancer incidence registration in German cancer registries , 2019, Annals of Cancer Epidemiology.

[69]  R. Wood,et al.  Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage , 2019, BMC Cancer.

[70]  M. Donia,et al.  The real-world impact of modern treatments on the survival of patients with metastatic melanoma. , 2019, European journal of cancer.

[71]  Prashanth Rawla,et al.  Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors , 2019, Przeglad gastroenterologiczny.

[72]  Catriona Manville,et al.  Factors affecting access to treatment of early breast cancer: Case studies from Brazil, Canada, Italy, Spain and UK: Implications for future research, policy and practice , 2019 .

[73]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[74]  Carola Berking,et al.  Melanoma , 2018, The Lancet.

[75]  J. Gershenwald,et al.  The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care , 2018, Expert review of anticancer therapy.

[76]  K. Straif,et al.  The IARC Perspective on Colorectal Cancer Screening. , 2018, The New England journal of medicine.

[77]  M. Di Maio,et al.  A review of guidelines for lung cancer. , 2018, Journal of thoracic disease.

[78]  W. Olszewski,et al.  NSCLC molecular testing in Central and Eastern European countries , 2018, BMC Cancer.

[79]  P. Potemski,et al.  Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective analysis of patients treated under drug/reimbursement programmes in Poland in 2013–2016 , 2018, Melanoma research.

[80]  M. Rutter,et al.  Colorectal Cancer Screening—Who, How, and When? , 2018, Clinical endoscopy.

[81]  K. Hata,et al.  Comparison of the guidelines for colorectal cancer in Japan, the USA and Europe , 2017, Annals of gastroenterological surgery.

[82]  S. Vogler,et al.  Medicines reimbursement policies in Europe , 2018 .

[83]  Personalised Medicine - Bringing Innovation to the Healthcare System , 2017, Biomedicine Hub.

[84]  M. Buljan,et al.  Health and Economic Burden of Skin Melanoma in Croatia - Cost-of-illness Study. , 2017, Acta dermatovenerologica Croatica : ADC.

[85]  I. Zalaudek,et al.  More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. , 2017, European journal of cancer.

[86]  Hiroki Nagai,et al.  Cancer prevention from the perspective of global cancer burden patterns. , 2017, Journal of thoracic disease.

[87]  H. Thulesius,et al.  The 2015 National Cancer Program in Sweden: Introducing standardized care pathways in a decentralized system. , 2016, Health policy.

[88]  G. Benčina Metastatic Colorectal Cancer In Croatia - Cost of Disease Study , 2016 .

[89]  Jie He,et al.  Epidemiology of Lung Cancer. , 2016, Surgical oncology clinics of North America.

[90]  C. la Vecchia,et al.  Risk factors for lung cancer worldwide , 2016, European Respiratory Journal.

[91]  Josep Malvehy,et al.  Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. , 2012, European journal of cancer.

[92]  Hassan Lemjabbar-Alaoui,et al.  Lung cancer: Biology and treatment options. , 2015, Biochimica et biophysica acta.

[93]  S. Dalton,et al.  Incidence of In Situ and Invasive Melanoma in Denmark From 1985 Through 2012: A National Database Study of 24,059 Melanoma Cases. , 2015, JAMA dermatology.

[94]  A. Saß,et al.  [Participation in cancer screening in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. , 2013, Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz.

[95]  Cost profiles of colorectal cancer patients in Italy based on individual patterns of care , 2013, BMC Cancer.

[96]  A. Saß,et al.  Inanspruchnahme von Krebsfrüherkennungsuntersuchungen , 2013, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.

[97]  M. Trudeau,et al.  International variability in the reimbursement of cancer drugs by publically funded drug programs. , 2012, Current oncology.

[98]  M. Federico,et al.  Differences in Stage and Treatment of Breast Cancer across Italy Point to Inequalities in access to and Availability of Proper Care , 2012 .

[99]  D. Morton,et al.  Surgery for distant melanoma metastasis. , 2012, Cancer journal.

[100]  J. Becker,et al.  [Treatment of advanced metastatic melanoma]. , 2011, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[101]  Peter B. Gahan,et al.  Overview of healthcare in the UK , 2010, EPMA Journal.

[102]  B. Larsen [Colorectal cancer screening]. , 2010, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[103]  E. Winer,et al.  International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured? , 2010, Journal of the National Cancer Institute.

[104]  L. Dušek,et al.  Colorectal cancer screening in Europe. , 2009, World journal of gastroenterology.

[105]  P. Kanavos,et al.  Colorectal cancer management in the United Kingdom: current practice and challenges , 2009, The European Journal of Health Economics.

[106]  P. Kanavos,et al.  The dynamics of colorectal cancer management in 17 countries , 2009, The European Journal of Health Economics.

[107]  P. Kanavos,et al.  The burden of colorectal cancer: prevention, treatment and quality of services , 2009, The European Journal of Health Economics.

[108]  W. Schurer,et al.  Cancer management and reimbursement aspects in Germany: an overview demonstrated by the case of colorectal cancer , 2009, The European Journal of Health Economics.

[109]  A. Hauschild,et al.  Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. , 2008, Melanoma research.

[110]  K. Pantel,et al.  Occult epithelial tumor cells detected in bone marrow by an enzyme immunoassay specific for cytokeratin 19 , 1997, International journal of cancer.

[111]  S. Ciatto,et al.  Cancer screening in the European Union. , 1994, European journal of cancer.

[112]  L. Ger,et al.  [Risk factors of lung cancer]. , 1992, Journal of the Formosan Medical Association = Taiwan yi zhi.

[113]  S. Leff What is Cancer , 1970 .